A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation by Stratford, M, Folkes, L

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescenc... by Stratford, M, Folkes, L

The influence of hydroquinone on tyrosinase kinetics by Stratford, M, Ramsden, C, Riley, P

Studies of para-quinomethane formation during the tyrosinase-catalyzed oxidation of 4-alkylcatechols by Land, E, Ramsden, C, Riley, P, Stratford, M

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells by Al-Assar, O, Bittner, M, Lunardi, S, Stratford, M, McKenna, W, Brunner, T

The horseradish peroxidase/indole-3-acetic acid combination for enzyme prodrug therapy: RROM in vitro to in vivo. by Tupper, J, Greco, O, Stratford, M, Tozer, G, Wardman, P, Dachs, G

Facts and artefacts in the use of fluorescent and luminescent probes for oxidative and nitrosative stress by Wardman, P, Burkitt, M, Lawrence, A, Patel, K, Stratford, M, Vojnovic, B

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. by Rustin, G, Galbraith, S, Anderson, H, Stratford, M, Folkes, L, Sena, L, Gumbrell, L, Price, P

Rates of reductive elimination of substituted nitrophenols from the (indol-3-yl)methyl position of indolequinones by Swann, E, Moody, C, Stratford, M, Patel, K, Naylor, M, Vojnovic, B, Wardman, P, Everett, SA

Systemic inflammation alters central 5-HT function as determined by pharmacological MRI. by Couch, Y, Martin, C, Howarth, C, Raley, J, Khrapitchev, A, Stratford, M, Sharp, T, Sibson, N, Anthony, D

Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia by Kelly, C, Hussien, K, Fokas, E, Kannan, P, Shipley, R, Ashton, T, Stratford, M, Pearson, N, Muschel, R

Systemic inflammation alters central 5-HT function as determined by pharmacological MRI. by Couch, Y, Martin, C, Howarth, C, Raley, J, Khrapitchev, A, Stratford, M, Sharp, T, Sibson, N, Anthony, D

Development of an enzymatic pretargeting strategy for dual-modality imaging. by Knight, J, Mosley, M, Stratford, M, Uyeda, H, Benink, H, Cong, M, Fan, F, Faulkner, S, Cornelissen, B

Systemic inflammation alters central 5-HT function as determined by pharmacological MRI (vol 75, pg 177, 2013) by Couch, Y, Martin, C, Howarth, C, Raley, J, Khrapitchev, A, Stratford, M, Sharp, T, Sibson, N, Anthony, D

Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. by Kelly, C, Hussien, K, Fokas, E, Kannan, P, Shipley, R, Ashton, T, Stratford, M, Pearson, N, Muschel, R

Corrigendum to "Systemic inflammation alters central 5-HT function as determined by pharmacological MRI" [Neuroimage 75 (2013) 177-186] by Couch, Y, Martin, C, Howarth, C, Raley, J, Khrapitchev, A, Stratford, M, Sharp, T, Sibson, N, Anthony, D

Iminoxyl radicals and stable products from the one-electron oxidation of 1-methylindole-3-carbaldehyde oximes by Everett, SA, Naylor, M, Stratford, M, Patel, K, Ford, E, Mortensen, A, Ferguson, A, Vojnovic, B, Wardman, P

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. by Fokas, E, Im, J, Hill, S, Yameen, S, Stratford, M, Beech, J, Hackl, W, Maira, S, Bernhard, E, Mckenna, W, Muschel, R

Controlling the rates of reductively-activated elimination from the (indol-3-yl)methyl position of indolequinones by Everett, SA, Naylor, M, Barraja, P, Swann, E, Patel, K, Stratford, M, Hudnott, A, Vojnovic, B, Locke, R, Wardman, P, Moody, C

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours by Roberts, C, Strauss, VY, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, LK, Stratford, M, Nicum, S